PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bmjThis ArticleThe BMJ
 
BMJ. 2007 May 19; 334(7602): 1020.
PMCID: PMC1871794
Drug Money for Patient Groups

The illusion of invulnerability

Peter R Mansfield, director, Healthy Skepticism Inc

Kent claims that patient groups are not naive, value their independence fiercely, and are quite capable of spotting the strings that may be attached to funding.1 Many doctors have similar overconfident beliefs about invulnerability to being misled by drug companies.2 This illusion of invulnerability actually increases vulnerability.3

In the 1840s doctors did not understand the risk of invisible microbes so were offended by the suggestion they should wash their hands. We are now going through a similar paradigm shift towards understanding the risk of invisible unintended bias from exposure to industry influence techniques. These techniques include manipulation of reciprocal obligation, which can occur without our awareness.4 Patient groups tend to reciprocate by lobbying governments to pay for overpriced drugs rather than lobbying the companies to reduce their prices.

Funding for patient groups could be increased and the alleged problems with government funding reduced by abolishing patents to allow price competition and using the savings to fund research, education, health promotion, and other activities of patients' groups through competitive grants.5

Notes

Competing interests: Healthy Skepticism is funded by individual subscriptions and occasional small contracts. In the past 5 years we have provided services for many organisations including universities, Consumers International, Der Arzneimittelbrief (Germany), Drugs and Therapeutics Information Service (Australia), Health Action International, National Prescribing Service (Australia) and the Royal Australasian College of Physicians.

References

1. Kent A. Should patient groups accept money from drug companies? Yes. BMJ 2007;334:934 (5 May.) [PMC free article] [PubMed]
2. Mansfield PR, Lexchin J, Wen LS, Grandori L, McCoy CP, Hoffman JR, et al. Educating health professionals about drug and device promotion: advocates' recommendations. PLoS Med 2006:3(11):e451.
3. Sagarin BJ, Cialdini RB, Rice WE, Serna SB. Dispelling the illusion of invulnerability: the motivations and mechanisms of resistance to persuasion. J Pers Soc Psychol 2002;83:526-41. [PubMed]
4. Dana J, Loewenstein G. A social science perspective on gifts to physicians from industry. JAMA 2003;290:252-5. [PubMed]
5. Mansfield P. Industry-sponsored research: a more comprehensive alternative. PLoS Med 2006;3:e463. [PMC free article] [PubMed]

Articles from The BMJ are provided here courtesy of BMJ Publishing Group